Skip to Content
Merck
  • A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia.

A genome-wide association study identifies novel loci associated with susceptibility to chronic myeloid leukemia.

Blood (2011-05-05)
Dong Hwan Dennis Kim, Seung-Tae Lee, Hong-Hee Won, Seonwoo Kim, Min-Ji Kim, Hee-Jin Kim, Sun-Hee Kim, Jong-Won Kim, Hyeoung-Joon Kim, Yeo-Kyeoung Kim, Sang Kyun Sohn, Joon Ho Moon, Chul Won Jung, Jeffrey H Lipton
ABSTRACT

In the current study, we identified 2 genetic markers for susceptibility to chronic myeloid leukemia (CML) using a genome-wide analysis. A total of 2744 subjects (671 cases and 2073 controls) were included, with 202 Korean CML patients and 497 control subjects enrolled as a discovery set. Significant findings in the discovery set were validated in a second Korean set of 237 patients and 1000 control subjects and in an additional Canadian cohort of European descent, including 232 patients and 576 control subjects. Analysis revealed significant associations of 2 candidate loci, 6q25.1 and 17p11.1, with CML susceptibility, with the lowest combined P values of 2.4 × 10⁻⁶ and 1.3 × 10⁻¹², respectively. Candidate genes in those regions include RMND1, AKAP12, ZBTB2, and WSB1. The locus 6q25.1 was validated in both Korean and European cohorts, whereas 17p11.1 was validated only in the Korean cohort. These findings suggest that genetic variants of 6q25.1 and 17p11.1 may predispose one to the development of CML.